Fountain Nathan B 4

4 · Acumen Pharmaceuticals, Inc. · Filed Jun 5, 2026

AI-generated summary of this filing

Updated Jun 5, 2026

Acumen Pharmaceuticals (ABOS) Director Nathan Fountain Receives Award

What Happened

Nathan B. Fountain, a director of Acumen Pharmaceuticals, was granted equity awards on 2026-06-03: 35,500 restricted stock units (RSUs) and a 53,250-share derivative award. Both awards were granted at $0.00 (no cash exchanged), totaling 88,750 contingent shares.

Key Details

Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely filing).
Grant type/code: A = Award/Grant. Reported prices: $0.00 for both grants (no purchase/sale proceeds).
Vesting: Per filing footnotes, the 35,500 RSUs vest in full on the earlier of the first anniversary of the grant or the 2027 annual meeting, subject to continuous service (F1). The 53,250 derivative award is subject to the same earlier-of schedule and continuous-service vesting (F2).
Shares owned after the transaction: not specified in the summary provided; see the full Form 4 for post-transaction holdings.
No indication of a 10b5-1 plan, tax withholding event, or sale — these are compensation awards.

Context

These awards are compensation for director service and vest over time; they are not purchases or sales and therefore do not represent an immediate bullish or bearish trade by the insider.
Derivative/option-style language in the footnotes means the second grant is contingent and subject to vesting conditions rather than an exercised, immediately tradable share grant.

Form 4

Period: 2026-06-03

Director

Transactions

Award
Common Stock
[F1]
2026-06-03+35,500→ 54,550 total
Award
Stock Option (right to buy)
[F2]
2026-06-03+53,250→ 53,250 total
Exercise: $2.29Exp: 2036-06-03→ Common Stock (53,250 underlying)

Footnotes (2)

[F1]Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
[F2]The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Signature

/s/ Derek Meisner, Attorney-in-Fact|2026-06-05

1 file